|
Press Releases |
|
 |
|
Tuesday, December 6, 2022 |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
Leading pharma companies GSK, Sanofi and Takeda will partner with research communities from the Agency for Science, Technology and Research (A*STAR); National University of Singapore (NUS); Nanyang Technological University, Singapore (NTU Singapore) and its innovation and enterprise company, NTUitive; and Singapore Institute of Technology (SIT) to boost Singapore's biologics manufacturing capabilities. more info >> |
|
Thursday, June 2, 2022 |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. more info >> |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
more info >> |
|
Thursday, September 30, 2021 |
|
A*STAR and Local SME Work with Vaccination Centres to Deploy AVID System for Filling Syringes |
The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for the vaccination centres which are set up by the Ministry of Health and operated by private healthcare providers. more info >> |
|
Friday, July 31, 2020 |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving "First Patient First Visit[1]" in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers. more info >> |
|
Friday, July 24, 2020 |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
MP Biomedicals Asia Pacific Pte Ltd, a diagnostic corporation which has been operating for over 30 years focusing on various infectious disease testing development and manufacturing, today announced the successful development of a rapid antibody test kit for COVID-19, in collaboration with the Agency for Science, Technology and Research (A*STAR). more info >> |
|
Tuesday, October 22, 2019 |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
Fujitsu Limited, the Singapore Management University (SMU) and the Agency for Science, Technology and Research (A*STAR)'s Institute of High Performance Computing today announced the launch of the Digital Platform Experimentation Project. more info >> |
|
Friday, June 28, 2019 |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
The nation's drug development efforts have been given additional momentum with the introduction of two new platforms, and a grant scheme for drug discovery and development. more info >> |
|
Friday, April 5, 2019 |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
It is with deep regret that the Agency for Science, Technology and Research (A*STAR) announces the passing of Dr Sydney Brenner, Honorary Singapore Citizen, and A*STAR Senior Fellow, early this morning. more info >> |
|
Monday, January 21, 2019 |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
Researchers at A*STAR's Singapore Bioimaging Consortium (SBIC) have discovered that branched-chain amino acids (BCAAs) in tumours can be targeted to prevent and treat cancer. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
GMG Unveils G(R) Lubricant Engine Performance Testing Results: A Transformative Graphene Energy Saving Solution for the Multi Trillion Dollar Global Liquid Fuel Industry
Feb 24, 2025 21:59 HKT/SGT
|
|
|
CALB (3931.HK) Announced a Positive Profit Alert
Feb 24, 2025 20:32 HKT/SGT
|
|
|
Hong Kong rated as leading sustainable business hub
Feb 24, 2025 18:13 HKT/SGT
|
|
|
Blackrock Silver Steps Out and Hits Multiple +1 kg/t AgEq Intercepts in First Assays from Resource Expansion Program at Tonopah West
Feb 24, 2025 18:09 HKT/SGT
|
|
|
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Third Consecutive Year
Feb 24, 2025 13:47 HKT/SGT
|
|
|
A Bold Experiment: Red Notice Coin (RNC) Drops a Game-Changer in the Crypto World
Feb 24, 2025 13:00 HKT/SGT
|
|
|
HKIRA 11th IR Awards 2025 now open for nomination
Feb 24, 2025 12:52 HKT/SGT
|
|
|
Mitsubishi and ENEOS to conduct Front End Engineering Design for Sustainable Aviation Fuel (SAF) Production at the Wakayama Refinery
Feb 24, 2025 12:30 JST
|
|
|
"Hong Kong Holiday & Travel Expo 2025" Successfully Concludes
Feb 24, 2025 11:21 HKT/SGT
|
|
|
CALB (3931.HK) Included in the Hang Seng Composite Index
Feb 23, 2025 21:59 HKT/SGT
|
|
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|